Dopamine-depleting agents can cause neuroleptic malignant syndrome, suggesting that dopamine depletion plays a pathogenetic role in this syndrome.
Answers are grounded in this paper and cite their sources.
May warrant caution with dopamine-depleting agents in Huntington disease; hypothesis-generating for dopamine depletion in neuroleptic malignant syndrome pathogenesis.
Prior reports of neuroleptic malignant syndrome (NMS) concerned patients with psychiatric disorders, usually schizophrenia, who were taking dopamine receptor blocking agents. We report the syndrome in a patient with Huntington disease who was treated with dopamine-depleting agents. He had a negative evaluation for malignant hyperthermia (MH), and we suggest that NMS differs from MH. The occurrence of NMS caused by dopamine-depleting agents suggests that anticholinergic properties of phenotiazines are not the only cause. Central dopaminergic systems probably participate in thermoregulation, and dopamine depletion probably plays a pathogenetic role in this syndrome.
No takes yet. Share an insight, caveat, or question.
Burke et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: